News and press releases
ASI invests in clinical research company EGeen. January 30, 2008 Tallinn, January 30, 2008 – The investment group Ambient Sound Investments (ASI) has acquired a stake in EGeen – a clinical research company that conducts clinical trials of drugs for American and European clients. CEO of EGeen International speaks at the 8th Annual C21 Bioventures Conference. April 17, 2006 Kalev Kask, the CEO of EGeen International, will be discussing opportunities of international strategies to speed up the drug development times and to lower the cost of bringing new medicines to the market as an invited panelist at the 8th Annual C21 Bioventures Conference on May 25, 2006, in Monterey, California. Mountain View, CA. - April 17, 2006. Kalev Kask, the CEO of EGeen International, will be discussing opportunities of international strategies to speed up the drug development times and to lower the cost of bringing new medicines to the market as an invited panelist at the TIEcon 2006 Conference "Disruption and Convergence - Entrepreneurship Unlimited" on May 12, 2006, in Santa Clara, California. Grannus BioSciences Limited Announces Appointment of EGeen as CRO. December 12, 2005 December 12, 2005 - Grannus BioSciences Ltd (GBL), a bio-pharmaceutical company developing novel products to control inflammatory and hyperproliferative disorders, announced today the appointment of EGeen AS, a subsidiary of EGeen International, as CRO for the Company's clinical development activities. Under the terms of the agreement, Grannus will utilize EGeen for the clinical testing of its lead biologic and small molecule therapeutics in Phase I and II human clinical trials respectively against a number of dermatologic diseases and conditions. EGeen Announces the Expansion of Clinical Development Capabilities. April 8, 2005 Mountain View, CA. - April 8, 2005 - EGeen International announced today the ongoing expansion of its clinical development capabilities. Specifically, the company has completed an addition of physician's networks and geographical expansion from Estonia to the other Baltic States and Ukraine. The company also appointed two key additional management team members: Mr. Ants Prümmel as its General Manager of its European subsidiary and promoted Dr. Lia Loime to its Head of Quality Assurance and Monitoring. EGeen Announces the Expansion of Management Team. July 2, 2003 FOSTER CITY, Calif. - July 2, 2003 - /PRNewswire/ - EGeen International announced today the appointments of Elizabeth S. Song, Ph.D., as its Vice President of Business Development, and Margus Annuk, M.D. Ph.D., as its Director of Clinical Development. Redwood City, CA, and San Diego, CA. - February 28, 2003 - EGeen International and Prediction Sciences announced today the signing of an agreement to collaborate on the discovery of genetic variants responsible for variable patient response to major classes of hypertension drugs. Financial details of the agreement were not disclosed. Monterey CA. - February 21, 2003 - Kalev Kask, the CEO of EGeen International, discussed as an invited panelist the future of emerging digital medicine at the Future of Life Meeting (www.thefutureoflife.com) organized by TIME Magazine to mark the fiftieth anniversary of the discovery of DNA double helix by Watson and Crick. Redwood City, CA, and San Diego, CA. - January 13, 2003 - EGeen International and Prediction Sciences announced today the signing of an agreement to collaborate on the study and discovery of genetic variants responsible for variable patient response to paroxetine (Paxil™), a major anti-depressant of the SSRI family. EGeen will receive milestone payments and royalties on future product sales. Further details of the agreement were not disclosed. Estonian Genome Project Ahead of Schedule. December 19, 2002 LONDON (Reuters Health) - A genome project set up by the tiny European country of Estonia is accelerating plans to take blood samples from three quarters of its population. EGeen International completes $4.25 Million in First Venture Financing Round. November 18, 2002 Redwood City, CA. - November 18, 2002 - EGeen International Corporation (EGeen), an emerging biotechnology company focused on population genetics, drug and diagnostic target discovery, and personalized medicine applications, announced today a completion of its first venture capital round of financing totaling $4.25 million. EGeen will use the funding to continue building the Estonian Gene Bank Foundation database and to expand its related commercial activities. Redwood City, CA - September 6, 2002 - EGeen and the Estonian Genome Project Foundation opened specially designed laboratory facilities for DNA sample processing and storage in Tartu, Estonia. The opening of the facilities is a major milestone in the three year long preparatory work to begin the collection of blood samples and medical data of the Estonian population. EGeen International and Prediction Sciences announced today the signing of an agreement to collaborate on the study and discovery of genetic variants responsible for variable patient response to citalopram (Celexa™) ... EGeen International Completes $2.0 Million Private Placement. April 2, 2002 EGeen International Corporation, a privately held emerging biotechnology company focused on population genetics, drug and diagnostic target discovery, and personalized medicine applications, announced today the completion of a $2.0 million private placement financing led by the SEAF CEE Growth Fund and The Baltics Small Equity Fund...
Estonian Genome Project Foundation Estonian Genome Foundation |